These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 30873584)
1. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Hapgood G; Ben-Neriah S; Mottok A; Lee DG; Robert K; Villa D; Sehn LH; Connors JM; Gascoyne RD; Feldman AL; Farinha P; Steidl C; Scott DW; Slack GW; Savage KJ Br J Haematol; 2019 Aug; 186(3):e28-e31. PubMed ID: 30873584 [No Abstract] [Full Text] [Related]
2. Small-cell pattern of DUSP22 rearranged ALK-negative anaplastic large-cell lymphoma with leukemic phase. Aarakaki H; Karube K Blood; 2022 Jan; 139(3):465. PubMed ID: 35050329 [No Abstract] [Full Text] [Related]
3. Discovery of G6PD deficiency in a patient with DUSP22-rearranged ALK-negative anaplastic large cell lymphoma in leukemic phase. Anderson J; Putnam E; Liu W; Menon MP Int J Lab Hematol; 2022 Feb; 44(1):67-68. PubMed ID: 34019742 [No Abstract] [Full Text] [Related]
4. Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. Ravindran A; Feldman AL; Ketterling RP; Dasari S; Rech KL; McPhail ED; Kurtin PJ; Shi M Am J Surg Pathol; 2021 Apr; 45(4):550-557. PubMed ID: 33165091 [TBL] [Abstract][Full Text] [Related]
5. Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. King RL; Dao LN; McPhail ED; Jaffe ES; Said J; Swerdlow SH; Sattler CA; Ketterling RP; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Gibson SE; Ondrejka SL; Nicolae A; Macon WR; Dasari S; Parrilla Castellar E; Feldman AL Am J Surg Pathol; 2016 Jan; 40(1):36-43. PubMed ID: 26379151 [TBL] [Abstract][Full Text] [Related]
6. [Detection of chromosomal translocations of DUSP22 and TP63 in ALK-negative anaplastic large cell lymphoma by fluorescence in situ hybridization and related clinical relevance]. Wang C; Chen X; Chen XY; He YH Zhonghua Bing Li Xue Za Zhi; 2019 Oct; 48(10):791-795. PubMed ID: 31594044 [No Abstract] [Full Text] [Related]
7. Progress in the identification of subgroups in ALK-negative anaplastic large-cell lymphoma. Boddicker RL; Feldman AL Biomark Med; 2015; 9(8):719-22. PubMed ID: 26223379 [No Abstract] [Full Text] [Related]
8. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Parrilla Castellar ER; Jaffe ES; Said JW; Swerdlow SH; Ketterling RP; Knudson RA; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Vasmatzis G; Gibson SE; Ondrejka S; Nicolae A; Grogg KL; Allmer C; Ristow KM; Wilson WH; Macon WR; Law ME; Cerhan JR; Habermann TM; Ansell SM; Dogan A; Maurer MJ; Feldman AL Blood; 2014 Aug; 124(9):1473-80. PubMed ID: 24894770 [TBL] [Abstract][Full Text] [Related]
9. Wang M; Kibbi N; Ring N; Siddon A; Foss F; Totonchy M BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31570354 [TBL] [Abstract][Full Text] [Related]
19. DUSP22 rearrangement in primary cutaneous T cell lymphoma with features intermediate between mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis. Diaz de la Pinta FJ; Machan S; Manso Alonso R; Carvajal N; Nieves Salgado R; Piris MA; Rodriguez-Pinilla SM Histopathology; 2022 Jan; 80(2):446-449. PubMed ID: 34252219 [No Abstract] [Full Text] [Related]